全球成像流式細胞技術市場規模（按產品、應用、技術、地區和預測）

成像流式細胞技術市場規模及預測

2023 年成像流式細胞技術市場規模價值 424.8 億美元，預計到 2032 年將達到 1,036.1 億美元，2026 年至 2032 年的複合年成長率為 11.79%。

成像流式細胞技術(IFC) 是一項革命性的技術，它將傳統流式細胞技術的定量能力與數位顯微鏡的視覺深度相結合，可以同時對大量單一細胞進行詳細分析和成像。

將流式細胞技術與成像相結合的概念自 20 世紀 70 年代末就已出現，但該領域的一些早期發展可以追溯到羅徹斯特大學的 Leon Wheeless，他致力於開發功能性成像流式細胞儀。

這項開創性的工作為現代 IFC 系統奠定了基礎，該系統後來不斷發展，可以提供高解析度影像並實現複雜的細胞分析。

近年來，IFC 因其能夠從有限的樣本量中提取更全面的數據（尤其是在單細胞層級）而廣受歡迎。這種能力在免疫學、腫瘤學和幹細胞研究等領域至關重要，因為了解單一細胞的特性至關重要。

IFC 將流式細胞技術的高通量和定量優勢與顯微鏡的可視化數據相結合，為研究人員提供了詳細研究細胞形態、表現型和功能的強大工具，使其在研究和臨床診斷應用中都具有不可估量的價值。

全球成像流式細胞技術市場動態

影響全球成像流式細胞技術市場的關鍵市場動態是：

關鍵市場促進因素

更重視免疫學和免疫腫瘤學研究：美國衛生研究院 (NIH) 預計，2020 年至 2023 年間，免疫學研究津貼將增加 35%。 2020 年至 2022 年間，涉及免疫腫瘤學流式細胞技術技術的臨床試驗數量將增加 45%。 2020 年至 2023 年，全球免疫學實驗室對成像流式細胞技術的採用率增加了 28%。

流式細胞技術技術在研究和臨床試驗中的應用日益廣泛：根據 Verified Market Research Analyst 的數據，2023 年全球流式細胞技術市場價值將達到 46.8554 億美元，到 2032 年將達到 80.66 億美元。 2020 年至 2022 年，流式細胞技術在藥物發現和開發活動中的使用增加了 32%。 2020 年至 2022 年，包含流式細胞技術的科學論文數量增加了 25%。

成像流式細胞技術的技術進步：2020 年至 2022 年，成像流式細胞技術技術研發的投資成長了 42%。 2020 年至 2023 年，成像流式細胞技術市場新產品發布數量增加了 38%。 2020 年至 2022 年，全球成像流式細胞技術儀儀器銷售額成長了 27%。 2020 年至 2022 年，人工智慧和機器學習在成像流式細胞技術分析中的整合成長了 33%。

主要挑戰

數據分析的複雜性和對專業知識的需求：從 2020 年到 2022 年，成像流式細胞技術數據分析所需的平均時間增加了 28%。從 2020 年到 2023 年，全球缺乏具備成像流式細胞技術資料分析專業知識的生物資訊專業人員。從 2020 年到 2022 年，用於成像流式細胞技術數據分析的專用軟體的成本增加了 25%。到 2022 年，45% 的研究人員將報告解釋成像流式細胞技術產生的複雜數據的挑戰。

設備和維護成本高：從 2020 年到 2022 年，成像流式細胞技術儀的平均價格上漲了 18%。從 2020 年到 2023 年，成像流式細胞技術儀的年度維護服務成本上漲了 22%。從 2020 年到 2022 年，成像流式細胞技術解決方案的總擁有成本上漲了 30%。 38% 的中小型實驗室認為預算限制是 2022 年採用成像流式細胞技術的主要障礙。

熟練技術人員短缺：2020 年至 2023 年，全球操作和維護成像流式細胞技術儀的訓練有素的人員短缺增加了 27%。從 2020 年到 2022 年，訓練成像流式細胞技術儀新用戶所需的平均時間增加了 20%。 42% 的成像流式細胞技術使用者表示，到 2022 年，他們將很難找到熟練的技術人員來支援他們的儀器。

主要趨勢

高解析度成像的進步：從 2020 年到 2022 年，解析度為 0.5 μm 或更高的成像流式細胞技術儀儀器的數量增加了 55%。從 2020 年到 2023 年，構造化照明顯微鏡 (SIM) 等超高解析度成像技術在成像流式細胞技術中的應用成長了 42%。從 2020 年到 2022 年，利用高解析度成像流式細胞技術進行細胞形態分析的研究論文增加了 35%。

人工智慧與機器學習的融合：從 2020 年到 2022 年，人工智慧驅動的影像分析演算法在成像流式細胞技術軟體中的應用成長了 65%。從 2020 年到 2023 年，機器學習模型在成像流式細胞技術中用於自動細胞分類和識別的應用增加了 52%。 2022 年，人工智慧成像流式細胞技術解決方案的研發投資達到 8,500 萬美元，高於 2020 年的 5,200 萬美元。 48% 的成像流式細胞技術用戶報告稱，由於 2022 年人工智慧和機器學習技術的融合，數據分析效率有所提高。

微型可攜式成像流式細胞技術：緊湊型桌上型成像流式細胞技術儀的銷量從 2020 年到 2022 年成長了 38%。預計從 2020 年到 2023 年，可攜式手持式成像流式細胞技術儀的開發將成長 25%。與 2020 年相比，2022 年微型成像流式細胞技術解決方案在就地檢驗和現場應用中的採用率將增加 32%。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查時間表
• 先決條件
• 限制

第2章調查方法

• 資料探勘
• 二次調查
• 初步調查
• 專家建議
• 品質檢查
• 最終審核
• 數據三角測量
• 自下而上的方法
• 自上而下的方法
• 研究流程
• 資料來源

第3章執行摘要

• 成像流式細胞技術市場概覽
• 成像流式細胞技術市場製圖
• 成像流式細胞技術的絕對商機
• 成像流式細胞技術市場的吸引力
• 未來市場機會
• 全球市場區隔

第4章 市場展望

• 成像流式細胞技術市場轉型
• 成像流式細胞技術市場展望
• 市場促進因素
  • 研究和學術領域對成像流式細胞技術的需求日益成長
  • 隨著人工智慧平台擴大用於成像流式細胞儀，收益來源不斷擴大
• 限制因素
  • 產品成本高
  • 新興國家購買量有限
• 機會
  • 片上多成像流式細胞技術的發展推動了市場成長
• COVID19的影響
• 波特五力分析
  • 新進入者的威脅
  • 替代品的威脅
  • 供應商的議價能力
  • 買家的議價能力
  • 競爭對手之間的競爭強度
• 價值鏈分析
• 宏觀經濟分析

第5章 成像流式細胞技術市場（按產品）

• 概述
• 軟體與服務
• 套件和試劑
• 裝置

第6章 成像流式細胞技術市場（依應用）

• 概述
• 學術研究所
• 醫院及臨床檢測機構
• 製藥和生物技術公司

7. 成像流式細胞技術市場（按技術）

• 以微珠為基礎
• 基於細胞的流式細胞技術

8. 成像流式細胞技術市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 拉丁美洲
• 巴西
• 阿根廷
• 其他拉丁美洲
  • 中東和非洲
• 阿拉伯聯合大公國
• 沙烏地阿拉伯
• 南非
• 其他中東和非洲地區

第9章 競爭態勢

• 概述
• 各公司市場排名分析
• 區域足跡
• 公司在各行業的足跡
• 王牌矩陣
  • 積極的
  • 前線
  • 新興
  • 創新者

第10章 公司簡介

• LUMINEX CORPORATION
• MILTENYI BIOTEC
• DANAHER CORPORATION
• CORIOLIS PHARMA
• SYSMEX
• THERMO FISHER SCIENTIFIC
• YOKOGAWA FLUID IMAGING TECHNOLOGIES, INC.
• APOGEE FLOW SYSTEMS LTD.
• NEXCELOM BIOSCIENCE LLC
• BIO-RAD LABORATORIES, INC.

Imaging Flow Cytometry Market Size And Forecast

The Imaging Flow Cytometry Market size was valued at USD 42.48 Billion in 2023 and is projected to reach USD 103.61 Billion by 2032, growing at a CAGR of 11.79% from 2026 to 2032.

Imaging Flow Cytometry (IFC) is an innovative technique that merges the quantitative power of traditional flow cytometry with the visual depth of digital microscopy, enabling the detailed analysis and imaging of numerous individual cells simultaneously.

While the concept of integrating flow cytometry with imaging has been explored since the late 1970s, early developments in this field include efforts by Leon Wheeless at the University of Rochester, who worked on creating functional imaging flow cytometers.

This pioneering work laid the foundation for modern IFC systems, which have since evolved to provide high-resolution images and enable complex cell analysis.

In recent years, IFC has gained popularity due to its ability to extract more comprehensive data from limited sample volumes, especially at the single-cell level. This capability is critical in fields such as immunology, oncology, and stem cell research, where understanding individual cell characteristics is essential.

By combining the strengths of flow cytometry high-throughput and quantitative measurement with the visual data of microscopy, IFC offers researchers a powerful tool for studying cell morphology, phenotype, and function in intricate detail, making it invaluable in both research and clinical diagnostics.

Global Imaging Flow Cytometry Market Dynamics

The key market dynamics that are shaping the global imaging flow cytometry market include:

Key Market Drivers

Increasing Focus on Immunology and Immuno-oncology Research: Funding for immunology research increased by 35% at the National Institutes of Health (NIH) in the US between 2020 and 2023. The number of clinical trials involving flow cytometry techniques in immuno-oncology increased by 45% from 2020 to 2022. The adoption of imaging flow cytometry in immunology laboratories grew by 28% globally between 2020 and 2023.

Rising Adoption of Flow Cytometry Techniques in Research and Clinical Trials: According to the Verified Market Research Analyst, the Global Flow Cytometry Market was valued at USD 4685.54 Million in 2023 to reach a valuation of USD 8066 Million by 2032. Utilization of flow cytometry in drug discovery and development activities increased by 32% from 2020 to 2022. The number of scientific publications involving flow cytometry rose by 25% between 2020 and 2022.

Technological Advancements in Imaging Flow Cytometry: Investment in R&D for imaging flow cytometry technologies grew by 42% from 2020 to 2022. The number of new product launches in the imaging flow cytometry market increased by 38% between 2020 and 2023. Imaging flow cytometry instrument sales grew by 27% globally from 2020 to 2022. The integration of artificial intelligence and machine learning in imaging flow cytometry analysis increased by 33% from 2020 to 2022.

Key Challenges

Data Analysis Complexity and Expertise Requirements: The average time required for data analysis in imaging flow cytometry increased by 28% from 2020 to 2022. The global shortage of bioinformatics professionals with expertise in imaging flow cytometry data analysis grew by 32% between 2020 and 2023. The cost of specialized software for imaging flow cytometry data analysis increased by 25% from 2020 to 2022. 45% of researchers reported challenges in interpreting the complex data generated by imaging flow cytometry in 2022.

High Instrument and Maintenance Costs: The average price of imaging flow cytometry instruments increased by 18% from 2020 to 2022. The annual maintenance and service costs for imaging flow cytometry systems grew by 22% between 2020 and 2023. The total cost of ownership for imaging flow cytometry solutions increased by 30% from 2020 to 2022. 38% of small and medium-sized research laboratories reported budget constraints as a significant barrier to adopting imaging flow cytometry in 2022.

Limited Availability of Skilled Technicians: The global shortage of trained personnel for the operation and maintenance of imaging flow cytometry instruments grew by 27% from 2020 to 2023. The average time required for training new users on imaging flow cytometry systems increased by 20% between 2020 and 2022. 42% of imaging flow cytometry users reported challenges in finding qualified technicians to support their instrumentation in 2022.

Key Trends

Advancements in High-Resolution Imaging: The number of imaging flow cytometry instruments with a resolution of 0.5 μm or better increased by 55% from 2020 to 2022. The adoption of super-resolution imaging techniques, such as structured illumination microscopy (SIM), in imaging flow cytometry grew by 42% between 2020 and 2023. Research publications utilizing high-resolution imaging flow cytometry for cellular morphology analysis increased by 35% from 2020 to 2022.

Integration of Artificial Intelligence and Machine Learning: The incorporation of AI-powered image analysis algorithms in imaging flow cytometry software increased by 65% from 2020 to 2022. The use of machine learning models for automated cell classification and identification in imaging flow cytometry grew by 52% between 2020 and 2023. Investment in R&D for AI-enabled imaging flow cytometry solutions reached $85 million in 2022, up from USD 52 Million in 2020. 48% of imaging flow cytometry users reported improved data analysis efficiency due to the integration of AI and ML technologies in 2022.

Miniaturization and Portable Imaging Flow Cytometry: The sales of compact, benchtop imaging flow cytometry instruments increased by 38% from 2020 to 2022. The development of portable, handheld imaging flow cytometry devices grew by 25% between 2020 and 2023. Adoption of miniaturized imaging flow cytometry solutions in point-of-care testing and field applications increased by 32% in 2022 compared to 2020.

Global Imaging Flow Cytometry Market Regional Analysis

Here is a more detailed regional analysis of the global imaging flow cytometry market:

North America

North America substantially dominates the Global Imaging Flow Cytometry Market driven by the robust healthcare expenditure and infrastructure.

The healthcare expenditure in the United States increased by 9.7% from 2020 to 2022, reaching USD 4.1 Trillion.

Canada's healthcare spending grew by 6.2% between 2020 and 2022, totaling $308 billion.

The number of accredited medical and clinical laboratories in North America increased by 15% from 2020 to 2023.

Investment in biomedical research and development in the US increased by 12% from 2020 to 2022.

Adoption of imaging flow cytometry instruments in the US and Canada increased by 32% between 2020 and 2023.

The number of academic and pharmaceutical research institutions utilizing imaging flow cytometry in North America rose by 28% from 2020 to 2022.

45% of global imaging flow cytometry system installations were in North America in 2022, up from 40% in 2020.

North America accounted for 55% of the global imaging flow cytometry market share in 2022, up from 50% in 2020.

The US FDA approved 20% more imaging flow cytometry-based diagnostic kits and reagents from 2020 to 2022.

Major imaging flow cytometry vendors, such as Luminex, Amnis (part of Merck), and Nexcelom Bioscience, have a significant presence in North America.

Government funding for imaging flow cytometry research and development in the US and Canada increased by 18% from 2020 to 2023.

Asia Pacific

Asia Pacific is anticipated to witness the fastest growth in the Global Imaging Flow Cytometry Market during the forecast period owing to the increasing biomedical research and clinical trials.

The Asia Pacific biotech and pharmaceutical R&D spending grew by 27% from 2020 to 2022.

The number of clinical trials involving flow cytometry techniques in the APAC region increased by 35% between 2020 and 2023.

Funding for immunology and oncology research in countries like China, Japan, and India rose by 42% from 2020 to 2022.

The APAC imaging flow cytometry market share increased from 35% in 2020 to 42% in 2022.

Healthcare spending in the Asia Pacific region grew by 15.4% from 2020 to 2022, reaching USD 2.1 Trillion.

The number of accredited medical laboratories in APAC increased by 18% between 2020 and 2023.

Investment in healthcare technology, including flow cytometry, increased by 28% in the APAC region from 2020 to 2022.

Government initiatives to improve diagnostic capabilities drove a 32% rise in imaging flow cytometry adoption from 2020 to 2022.

The demand for flow cytometry-based COVID-19 diagnostics and research grew by 65% in APAC from 2020 to 2022.

Imaging flow cytometry applications in vaccine development and immunology studies increased by 55% in the APAC region between 2020 and 2022.

Investment in imaging flow cytometry instrumentation by public and private healthcare institutions in the APAC region rose by 48% from 2020 to 2022.

The Asia Pacific imaging flow cytometry market is expected to grow at a CAGR of 12.6% from 2020 to 2023, outpacing other regions.

Global Imaging Flow Cytometry Market: Segmentation Analysis

The Global Imaging Flow Cytometry Market is segmented based on Product, Application, Technology, And Geography.

Imaging Flow Cytometry Market, By Product

• Software & Services
• Kits & Reagents
• Instruments

Based on the Product, the Global Imaging Flow Cytometry Market is bifurcated into Software & Services, Kits & Reagents, and Instruments. The instrument segment significantly dominates the global imaging flow cytometry market, driven by technological advancements like higher-resolution imaging and faster acquisition rates, which enhance data accuracy and analysis efficiency. These innovations support expanding applications across diverse research fields, including immunology, cancer biology, and stem cell research, where detailed cellular imaging is essential.

Imaging Flow Cytometry Market, By Application

• Academic & Research Institutes
• Hospitals & Clinical Testing Laboratories
• Pharmaceutical & Biotechnology Companies

Based on the Application, the Global Imaging Flow Cytometry Market is bifurcated into Academic & Research Institutes, Hospitals & Clinical Testing Laboratories, and Pharmaceutical & Biotechnology Companies. The Academic and Research Institutes segment dominates the global imaging flow cytometry market, driven by extensive research in fields like immunology, cancer biology, and stem cell studies. Rising demand for advanced cell analysis techniques, coupled with government funding and grants supporting research initiatives, further boosts the segment's prominence in this market.

Imaging Flow Cytometry Market, By Technology

• Bead-based
• Cell-based Flow Cytometry

Based on the Technology, the Global Imaging Flow Cytometry Market is bifurcated into Bead-based and Cell-based Flow Cytometry. The cell-based flow cytometry segment dominates the lobal imaging flow cytometry market, fueled by its ability to study cellular morphology, protein expression, and functional properties in detail. The growing demand for advanced cell analysis techniques across diverse research fields and its increasing adoption in clinical diagnostics further enhance this segment's leadership in the market.

Imaging Flow Cytometry Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Imaging Flow Cytometry Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America substantially dominates the Global Imaging Flow Cytometry Market driven by the robust healthcare expenditure and infrastructure. The healthcare expenditure in the United States increased by 9.7% from 2020 to 2022, reaching USD 4.1 Trillion. Canada's healthcare spending grew by 6.2% between 2020 and 2022, totaling USD 308 Billion. The number of accredited medical and clinical laboratories in North America increased by 15% from 2020 to 2023. Investment in biomedical research and development in the US increased by 12% from 2020 to 2022. Adoption of imaging flow cytometry instruments in the US and Canada increased by 32% between 2020 and 2023.

Key Players

The "Global Imaging Flow Cytometry Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Luminex Corporation, Miltenyi Biotec, Danaher Corporation, Coriolis Pharma, Sysmex, Thermo Fisher, Apogee Flow Systems Ltd., Yokogawa Fluid Imaging Technologies, Inc., Nexcelom Bioscience LLC, Molecular Devices LLC.

• This section offers in-depth analysis through a company overview, position analysis, the regional and industrial footprint of the company, and the ACE matrix for insightful competitive analysis. The section also provides an exhaustive analysis of the financial performances of mentioned players in the given market.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Imaging Flow Cytometry Market Key Developments

• In May 2024, Luminex Corporation announced the launch of their next-generation imaging flow cytometer, which boasts 50% higher throughput and superior AI-powered data analytics capabilities.
• In January 2024, Sysmex Corporation announced the acquisition of a top European imaging flow cytometry technology firm therefore boosting its product line and expanding its global footprint.
• In June 2023, Miltenyi Biotec announced a collaboration with a prominent US academic university to develop AI-driven algorithms for automatic cell classification in image flow cytometry applications.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL IMAGING FLOW CYTOMETRY MARKET OVERVIEW
• 3.2 GLOBAL IMAGING FLOW CYTOMETRY ECOLOGY MAPPING
• 3.3 GLOBAL IMAGING FLOW CYTOMETRY ABSOLUTE MARKET OPPORTUNITY
• 3.4 GLOBAL IMAGING FLOW CYTOMETRY MARKET ATTRACTIVENESS
• 3.5 GLOBAL IMAGING FLOW CYTOMETRY MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.6 GLOBAL IMAGING FLOW CYTOMETRY MARKET, BY COMPONENT (USD MILLION)
• 3.7 GLOBAL IMAGING FLOW CYTOMETRY MARKET, BY APPLICATION (USD MILLION)
• 3.8 FUTURE MARKET OPPORTUNITIES
• 3.9 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

• 4.1 GLOBAL IMAGING FLOW CYTOMETRY MARKET EVOLUTION
• 4.2 GLOBAL IMAGING FLOW CYTOMETRY MARKET OUTLOOK
• 4.3 MARKET DRIVERS
  • 4.3.1 THE GROWING NEED FOR IMAGING FLOW CYTOMETRY IN RESEARCH AND ACADEMIA
  • 4.3.2 RISING INCORPORATION OF AI PLATFORMS FOR IMAGING FLOW CYTOMETER TO WIDEN THE REVENUE GATE
• 4.4 RESTRAINTS
  • 4.4.1 SIGNIFICANT PRODUCT COST TO HAMPER ADOPTION OF IMAGING FLOW CYTOMETRY
  • 4.4.2 LIMITED PURCHASE IN DEVELOPING COUNTRIES
• 4.5 OPPORTUNITY
  • 4.5.1 DEVELOPMENT OF ON CHIP MULTI IMAGING FLOW CYTOMETRY TO OPEN GATES FOR THRIVING MARKET
• 4.6 COVID19 IMPACT
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 THREAT OF SUBSTITUTES
  • 4.7.3 BARGAINING POWER OF SUPPLIERS
  • 4.7.4 BARGAINING POWER OF BUYERS
  • 4.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 MACROECONOMIC ANALYSIS

5 IMAGING FLOW CYTOMETRY MARKET, BY PRODUCT

• 5.1 OVERVIEW
• 5.2 SOFTWARE & SERVICES
• 5.3 KITS & REAGENTS
• 5.4 INSTRUMENTS

6 IMAGING FLOW CYTOMETRY MARKET, BY APPLICATION

• 6.1 OVERVIEW
• 6.2 ACADEMIC & RESEARCH INSTITUTES
• 6.3 HOSPITALS & CLINICAL TESTING LABORATORIES
• 6.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

7 IMAGING FLOW CYTOMETRY MARKET, BY TECHNOLOGY

• 7.1 BEAD-BASED
• 7.2 CELL-BASED FLOW CYTOMETRY

8 IMAGING FLOW CYTOMETRY MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA-PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA-PACIFIC
• 8.5 LATIN AMERICA
• 8.6 BRAZIL
• 8.7 ARGENTINA
• 8.8 REST OF LATIN AMERICA
  • 8.8.1 MIDDLE EAST AND AFRICA
• 8.9 UAE
• 8.10 SAUDI ARABIA
• 8.11 SOUTH AFRICA
• 8.12 REST OF MEA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPANY MARKET RANKING ANALYSIS
• 9.3 COMPANY REGIONAL FOOTPRINT
• 9.4 COMPANY INDUSTRY FOOTPRINT
• 9.5 ACE MATRIX
  • 9.5.1 ACTIVE
  • 9.5.2 CUTTING EDGE
  • 8.5.3 EMERGING
  • 8.5.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 LUMINEX CORPORATION
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 COMPANY INSIGHTS
  • 10.1.3 SEGMENT BREAKDOWN
  • 10.1.4 PRODUCT BENCHMARKING
  • 10.1.5 CURRENT FOCUS & STRATEGIES
  • 10.1.6 THREAT FROM COMPETITION
  • 10.1.7 SWOT ANALYSIS
• 10.2 MILTENYI BIOTEC
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 COMPANY INSIGHTS
  • 10.2.3 PRODUCT BENCHMARKING
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 CURRENT FOCUS & STRATEGIES
  • 10.2.6 THREAT FROM COMPETITION
  • 10.2.7 SWOT ANALYSIS
• 10.3 DANAHER CORPORATION
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 COMPANY INSIGHTS
  • 10.3.3 SEGMENT BREAKDOWN
  • 10.3.4 CURRENT FOCUS & STRATEGIES
  • 10.3.5 THREAT FROM COMPETITION
  • 10.3.6 SWOT ANALYSIS
• 10.4 CORIOLIS PHARMA
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 COMPANY INSIGHTS
  • 10.4.3 CURRENT FOCUS & STRATEGIES
  • 10.4.4 THREAT FROM COMPETITION
  • 10.4.5 SWOT ANALYSIS
• 10.5 SYSMEX
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 COMPANY INSIGHTS
  • 10.5.3 SEGMENT BREAKDOWN
  • 10.5.4 PRODUCT BENCHMARKING
  • 10.5.5 CURRENT FOCUS & STRATEGIES
  • 10.5.6 THREAT FROM COMPETITION
  • 10.5.7 SWOT ANALYSIS
• 10.6 THERMO FISHER SCIENTIFIC
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 COMPANY INSIGHTS
  • 10.6.3 SEGMENT BREAKDOWN
  • 10.6.4 PRODUCT BENCHMARKING
  • 10.6.5 CURRENT FOCUS & STRATEGIES
  • 10.6.6 THREAT FROM COMPETITION
  • 10.6.7 SWOT ANALYSIS
  • 10.6.8 KEY DEVELOPMENTS
• 10.7 YOKOGAWA FLUID IMAGING TECHNOLOGIES, INC.
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 COMPANY INSIGHTS
  • 10.7.3 PRODUCT BENCHMARKING
  • 10.7.4 KEY DEVELOPMENTS
• 10.8 APOGEE FLOW SYSTEMS LTD.
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 COMPANY INSIGHTS
  • 10.8.3 PRODUCT BENCHMARKING
• 10.9 NEXCELOM BIOSCIENCE LLC
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 COMPANY INSIGHTS
  • 10.9.3 PRODUCT BENCHMARKING
• 10.10 BIO-RAD LABORATORIES, INC.
  • 10.10.1 BIO-RAD LABORATORIES, INC.
  • 10.10.2 COMPANY INSIGHTS
  • 10.10.3 SEGMENT BREAKDOWN
  • 10.10.4 PRODUCT BENCHMARKING